Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03944785 · ClinicalTrials.gov registry record
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
A clinical trial, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- 164
- Enrollment target
NCT03944785 is a clinical trial that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 164 participants.
The verdict
NCT03944785 has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- 164 participants
- Enrollment target
Study Summary
This is a Phase IV, prospective, observational, post-marketing study designed to obtain additional data on the effect of XADAGO on motor and non-motor symptoms in Parkinson's Disease patients newly prescribed XADAGO.
Interventions
- DRUG XADAGO (safinamide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2020-01-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03944785
The ClinicalTrials.gov registry entry for NCT03944785 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XADAGO (safinamide) is the first listed.
NCT03944785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03944785 about?
NCT03944785 is a clinical study titled "Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)". This is a Phase IV, prospective, observational, post-marketing study designed to obtain additional data on the effect of XADAGO on motor and non-motor symptoms in Parkinson's Disease patients newly prescribed XADAGO.
What is the current status of trial NCT03944785?
This trial is currently completed. The enrollment target is 164 participants. The study started on 2017-11-30. Estimated completion is 2020-01-10.
What interventions are being tested in trial NCT03944785?
The interventions under investigation include: XADAGO (safinamide) (DRUG).
Who is sponsoring clinical trial NCT03944785?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.